NEW YORK, Jan. 8, 2018 /PRNewswire/
-- Oppenheimer & Co. Inc. ("Oppenheimer") – a
leading wealth manager and investment bank and a subsidiary of
Oppenheimer Holdings (NYSE: OPY) – today announced a continued
emphasis on the Firm's healthcare business, including significant
investments across its healthcare investment banking, research, and
institutional equity sales teams.
In 2017, the Firm added a new Life Sciences team within the
Healthcare Investment Banking group led by Michael A. Margolis, R.Ph. who serves as
Managing Director and Co-Head of Healthcare Investment Banking,
along with Marc Cabrera who leads
the Healthcare Services and Digital Health team. Recent additions
to the team also include:
- Stefan D. Loren, Ph. D.,
Managing Director, Healthcare: Dr. Loren has held positions on
both the buy-side and sell-side, as well as corporate positions
within the pharmaceutical and biotech industry. His deep
relationships and domain expertise complement the firm's overall
banking efforts.
- Eric Tansky, Managing
Director, Healthcare: Mr. Tansky specializes in medical
devices, and throughout his career has executed over 40 M&A and financing transactions with an
aggregate value of approximately $50
billion. His range of strategic transaction experience
includes sell-side and buy-side M&A advisory, hostile
take-over, and defense advisory assignments.
- David Newcomb, Managing
Director, Equities: Mr. Newcomb's sales experience will be a
key factor in the continued expansion of Oppenheimer's healthcare
platform. His expertise and relationships will help expand the
reach of the firm's healthcare product with access to an increased
number of institutional equity accounts.
These additions will continue the Firm's successful track record
in the healthcare sector. Over the last decade, Oppenheimer's
healthcare banking professionals have advised on approximately 300
deals including advisory services for transactions totaling
approximately $13 billion and
financings totaling approximately $30
billion.
"Oppenheimer has a long history of providing healthcare
companies with access to capital markets and industry leading
advisory services. With these latest additions, we will be better
positioned to serve the growing needs of our clients," said
Robert Lowenthal, Head of
Oppenheimer Investment Banking.
Oppenheimer & Co. Inc.
Oppenheimer & Co. Inc.
(Oppenheimer), a principal subsidiary of Oppenheimer Holdings Inc.
(OPY on the New York Stock Exchange), and its affiliates provide a
full range of wealth management, securities brokerage and
investment banking services to high-net-worth individuals,
families, corporate executives, local governments, businesses and
institutions.
View original
content:http://www.prnewswire.com/news-releases/oppenheimer-reinforces-commitment-to-healthcare-investment-banking-with-new-hires-and-continued-focus-in-2018-300578968.html
SOURCE Oppenheimer & Co. Inc.